Ruxolitinib ni molekile ntoya Janus kinase inhibitor ikoreshwa mukuvura myelofibrosis yo hagati cyangwa ibyago byinshi hamwe nuburyo bwihanganira polycythemia vera nindwara ya graft-vs-host. Ruxolitinib ifitanye isano nigihe gito kandi mubisanzwe byoroheje muri serumu aminotransferase mugihe cyo kuvura ndetse no mubihe bidasanzwe byo kwikomeretsa, kugaragara kwa clinique idiosyncratic bikabije byumwijima kimwe nibibazo byo kongera kwandura hepatite B kubantu bakunze kwibasirwa.

Ruxolitinib ni bioavailable mu kanwa Janus ifitanye isano na kinase (JAK) inhibitor hamwe nibikorwa bya antineoplastique na immunomodulation. Ruxolitinib ihuza cyane kandi ikabuza poroteyinetyrosinekinase JAK 1 na 2, zishobora gutuma kugabanuka k'umuriro no kubuza ikwirakwizwa rya selile. Inzira ya JAK-STAT (transducer signal na activate de transcription) inzira igira uruhare runini mukumenyekanisha cytokine nyinshi nibintu bikura kandi ikagira uruhare mukwiyongera kwa selile, gukura, hematopoiesis, hamwe no gukingira indwara; JAK kinase irashobora gutegekwa muburwayi bwindwara, indwara ya myeloproliferative, hamwe na malariya mbi.

Ruxolitinib ni apyrazoleyasimbuwe kumwanya wa 1 nitsinda rya 2-cyano-1-cyclopentylethyl naho kumwanya wa 3 nitsinda rya pyrrolo [2,3-d] pyrimidin-4-yl. Ikoreshwa nkumunyu wa fosifate mukuvura abarwayi bafite myelofibrosis yo hagati cyangwa ibyago byinshi, harimo myelofibrosis yibanze, post-polycythemia vera myelofibrosis na trombocythemia myelofibrosis. Ifite uruhare nka antineoplastique na EC 2.7.10.2 (proteine ​​idasanzwe-tyrosinekinase) inhibitor. Ni nitrile, apyrrolopyrimidinen'umunyamuryango wa pyrazoles.